Halozyme Reports Fourth Quarter And Full-Year 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Halozyme Therapeutics (HALO) PT Raised to $19 at BMO Capital
February 21, 2018 8:42 AM ESTBMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Do Kim said they believe ENHANZE continues to provide a strong valuation floor with Janssen conducting six studies. However, PEGPH20 Phase III interim data in 4Q18 remains a key risk.
... MoreHalozyme Therapeutics (HALO) PT Raised to $24 at Deutsche Bank
February 21, 2018 6:55 AM ESTDeutsche Bank raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $24.00 (from $21.00) while maintaining a Buy rating following the company's 4Q earnings report. Results were in line with our expectations given the preliminary announcement of results earlier this year. +24.6% y/y royalty... More
Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates Outlook
February 20, 2018 4:07 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.85, $0.13 better than the analyst estimate of $0.72. Revenue for the quarter came in at $189.6 million versus the consensus estimate of $165.19 million.
Financial Outlook for 2018
Halozyme reiterated its financial guidance of:
Net revenue of $115 million to $125... More